vTv Therapeutics Inc. (NASDAQ:VTVT) and Strongbridge Biopharma plc (NASDAQ:SBBP) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|vTv Therapeutics Inc.||2||7.73||N/A||-0.73||0.00|
|Strongbridge Biopharma plc||4||7.48||N/A||0.85||3.04|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of vTv Therapeutics Inc. and Strongbridge Biopharma plc.
Table 2 shows us vTv Therapeutics Inc. and Strongbridge Biopharma plc’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|vTv Therapeutics Inc.||0.00%||18.1%||-111.3%|
|Strongbridge Biopharma plc||0.00%||79.3%||27.2%|
Risk & Volatility
A -3.65 beta indicates that vTv Therapeutics Inc. is 465.00% more volatile compared to Standard & Poor’s 500. Strongbridge Biopharma plc’s 19.00% less volatile than Standard & Poor’s 500 which is a result of the 0.81 beta.
vTv Therapeutics Inc.’s Current Ratio is 0.3 while its Quick Ratio is 0.3. On the competitive side is, Strongbridge Biopharma plc which has a 5.2 Current Ratio and a 5 Quick Ratio. Strongbridge Biopharma plc is better positioned to pay off short and long-term obligations compared to vTv Therapeutics Inc.
The next table highlights the given recommendations and ratings for vTv Therapeutics Inc. and Strongbridge Biopharma plc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|vTv Therapeutics Inc.||0||0||1||3.00|
|Strongbridge Biopharma plc||0||0||0||0.00|
vTv Therapeutics Inc.’s upside potential is 240.14% at a $5 average price target.
Institutional and Insider Ownership
vTv Therapeutics Inc. and Strongbridge Biopharma plc has shares owned by institutional investors as follows: 7.3% and 66.4%. About 69.32% of vTv Therapeutics Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.8% of Strongbridge Biopharma plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|vTv Therapeutics Inc.||0%||-1.41%||1.45%||-49.28%||14.75%||-47.17%|
|Strongbridge Biopharma plc||0%||-23.08%||-31.4%||-45.15%||-43.48%||-41.96%|
For the past year vTv Therapeutics Inc.’s stock price has bigger decline than Strongbridge Biopharma plc.
On 7 of the 9 factors Strongbridge Biopharma plc beats vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The companyÂ’s drug candidate for the treatment of AlzheimerÂ’s disease comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. Its type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials. The company has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutics, prophylactic, preventative, or diagnostic use. vTv Therapeutics Inc. was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. operates as a subsidiary of M&F TTP Holdings Two LLC.
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.